GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update March 30, 2023
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market December 30, 2022
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 December 12, 2022
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting November 10, 2022
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting November 3, 2022
